TABLE 3.
Initial antibiotic regimen and outcomes for patients with CDI/BSI compared to those of controls
| Variable | Value(s) by infection status |
P valuea | |
|---|---|---|---|
| CDI/BSI+ (n = 72) | CDI/BSI− (n = 321) | ||
| Oral vancomycin (no. [%]) | 61 (84.7) | 262 (81.6) | 0.7 |
| Metronidazole (no. [%]) | 11 (15.3) | 59 (18.4) | 0.4 |
| Escalation to oral vancomycin + metronidazole (no. [%]) | 25 (34.7) | 95 (29.6) | 0.1 |
| Oral vancomycin, >500 mg/day (no. [%]) | 51 (70.8) | 100 (31.1) | <0.001 |
| Transfer to ICU (no. [%]) | 14 (19.5) | 29 (9) | 0.002 |
| Days of ICU stay (no.) | 16.9 ± 4.4 | 9.1 ± 4.9 | <0.001 |
| Days of hospital stay (no.) | 62.2 ± 21.9 | 29.3 ± 13.2 | <0.001 |
| Time at risk for CDI (days) | 9.5 ± 1.4 | 11.1 ± 2.3 | 0.2 |
| Time at risk for CDI recurrence (days) | 20.4 ± 3.3 | 35.1 ± 6.2 | <0.001 |
| Severe sepsis or septic shock (no. [%]) | 61 (84.7) | 50 (15.7) | <0.001 |
| 30-Day mortality from CDI diagnosis (no. [%]) | 28 (38.9) | 42 (13.1) | 0.001 |
| Mortality attributable to BSI (no. [%]) | 41 (56.9) | ||
| All causes of in-hospital mortality (no. [%]) | 55 (76.3) | 70 (21.8) | <0.001 |
a
Values in boldface are significant.